Globus Medical, Inc. $GMED Shares Sold by Global Alpha Capital Management Ltd.

Global Alpha Capital Management Ltd. lessened its stake in Globus Medical, Inc. (NYSE:GMED) by 41.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 666,696 shares of the medical device company’s stock after selling 478,895 shares during the period. Globus Medical comprises approximately 3.6% of Global Alpha Capital Management Ltd.’s portfolio, making the stock its 4th largest position. Global Alpha Capital Management Ltd. owned 0.50% of Globus Medical worth $58,209,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC purchased a new position in Globus Medical in the third quarter valued at $26,000. EverSource Wealth Advisors LLC boosted its holdings in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. SBI Securities Co. Ltd. boosted its holdings in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the period. Parallel Advisors LLC boosted its holdings in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Globus Medical in the third quarter valued at $36,000. Institutional investors and hedge funds own 95.16% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GMED shares. Barclays lifted their target price on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wells Fargo & Company lowered their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Truist Financial set a $115.00 target price on shares of Globus Medical in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Stock Up 0.2%

NYSE GMED opened at $80.13 on Friday. The stock has a market capitalization of $10.88 billion, a P/E ratio of 18.63, a P/E/G ratio of 1.65 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The firm has a 50-day moving average price of $86.27 and a 200 day moving average price of $88.21.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.